HOME >> BIOLOGY >> NEWS
Activated signaling pathway may predict lung cancer patients' response to gefitinib

There are multiple signaling pathways in a cell that control its behavior, such as the ability to survive and divide rapidly. A new study in the August 4 issue of the Journal of the National Cancer Institute has found that, among patients with nonsmall-cell lung cancer (NSCLC) whose tumor cells contain a specific activated signaling pathway, the cancer drug gefitinib (Iressa) was associated with a better response rate, disease control rate, and time to progression compared with patients in whom the pathway was not activated.

NSCLC is the most common type of lung cancer. Less than 15% of patients with NSCLC are cured despite aggressive surgical and chemotherapeutic intervention. Gefitinib, a cancer drug that interferes with the epidermal growth factor receptor (EGFR) pathway, is active in approximately 10% of NSCLC patients in whom standard therapy has failed. Although earlier studies have found that the expression of EGFR alone does not predict whether a patient will respond to gefitinib, there are many signaling pathways that are dependent on EGFR expression.

To determine whether two such pathways--called Akt and MAPK--may be involved in a patient's response to gefitinib, Federico Cappuzzo, M.D., of Bellaria Hospital in Bologna, Italy, and colleagues, looked at the association between phosphorylation status (a measure of activation) of Akt and MAPK in tumors from 103 patients with NSCLC before they received treatment and any subsequent response to gefitinib.

The authors found that 51 patients had tumors that were positive for Akt phosphorylation (P-Akt). P-Akt positivity was associated with being female and having a history of never smoking. Patients with P-Aktpositive tumors had a better response rate, disease control rate (which includes complete and partial responses and stable disease), and time to progression than patients with P-Akt negative tumors. There was no difference in outcome according to MAPK phosyphorylation (P-MAPK)
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
3-Aug-2004


Page: 1 2

Related biology news :

1. NRH1 and Wnt signaling come together in convergent extension
2. From lung to gut the Wnt signaling pathway transforms cell fate
3. Equine clonings triple play sheds light on calcium, cell signaling, human disease
4. UT Southwestern researchers learn importance of insulin family signaling in male sex determination
5. Mantis shrimp fluoresce to enhance signaling in the dim ocean depths
6. OHSU researchers discover molecular signaling system controlling aspects of embryonic development
7. New study identifies gene signaling puberty
8. Are the bright colors of some avian eggs signaling female genetic quality to their mates?
9. Scientists map signaling molecule crucial to survival, disease
10. Researchers identify molecular signaling system that is crucial for plant fertility
11. Plants and people share a molecular signaling system, researchers discover

Post Your Comments:
(Date:5/24/2013)... one French Quarter neighborhood of New Orleans to determine ... Hurley, PhD, Assistant Professor of Audiology at LSU Health ... LSUHSC doctor of audiology student, recommend that people use ... case study is published online in the current issue ... important part of an audiologist,s practice is aiding patients ...
(Date:5/23/2013)... Tomatoes, said to be the world,s most popular fruit, ... UK research with purple GM varieties. , "Working ... only by the addition of a specific compound, allows ... traits," said Professor Cathie Martin from the John Innes ... varieties with better flavour, health and shelf life characteristics ...
(Date:5/23/2013)... estrogen suppresses lipid synthesis in the liver, UC Irvine ... certain liver diseases. , With this finding, Dr. ... views in the field. Study results appear in the ... . , "The dogma in the steroid receptor field ... in the nucleus respond to steroid hormones by regulating ...
Breaking Biology News(10 mins):Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
(Date:5/23/2013)... , May 23, 2013 BioTrends Research ... advisory firms for specialized biopharmaceutical issues, finds that, ... infectious disease specialists reported that in the past ... intentionally delaying treatment) in anticipation of the next ... months ago, when only 6 percent reported that ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
(Date:5/23/2013)... May 23, 2013  Verenium Corporation (Nasdaq: ... the development and commercialization of high-performance enzymes, today announced ... Officer, will present at two upcoming conferences. ... present at the Second Annual Marcum LLP Microcap Conference ... Hotel in New York City.  The presentation is scheduled ...
(Date:5/23/2013)... SynCardia Systems, Inc. ( http://www.syncardia.com ), ... Canada and CE (Europe) approved Total Artificial Heart, announced ... boasts more than 380,000 visitors annually, is featuring the ... the Freedom® portable driver as part of its $3 ... of its kind. , “BodyWorks combines the latest ...
Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
Cached News: